Five things for pharma marketers to know: Friday, June 2, 2017

Share this content:

1. Oncologists who receive meals and travel and engage in consulting partnerships with drugmakers are more likely to prescribe their drugs, a new study found. (Stat)

2. Tesaro is reportedly considering a sale. The company has a value of about $7.4 billion and in March received FDA approval to market ovarian-cancer drug Zejula, a PARP inhibitor. (WSJ)

3. AbbVie has the best reputation among drugmakers, followed by Novo Nordisk, Takeda, and Roche, according to a new report. Pfizer was ranked at the bottom for a second year in a row. (Law360)

4. As part of the #IAmHHS campaign, a staff supervisor in the FDA's Office of Prescription Drug Promotion talked about his role creating the Bad Ad Program that fights misleading ad claims by pharmaceutical companies. (FDA Voice)

5. The state of Ohio filed a lawsuit against Purdue Pharma, Johnson & Johnson, Endo, Teva Pharmaceutical Industries, and Allergen, alleging that they used misleading marketing tactics to get Ohio residents to receive unnecessary opioid prescriptions. The drugmakers denied the allegations. (Reuters)

Share this content:
Scroll down to see the next article